Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCTRLN)

Drug Name
OT-101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2/3 [1]
Merkel cell carcinoma 2C34 Phase 2/3 [1]
Pancreatic cancer 2C10 Phase 2/3 [2]
Recurrent glioblastoma 2A00.00 Phase 2/3 [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Cross-matching ID
TTD Drug ID
DMCTRLN

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF beta-2 messenger RNA (TGFB2 mRNA) TTI0KH6 TGFB2_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TGF beta-2 messenger RNA (TGFB2 mRNA) DTT TGFB2 5.307 4.868 4.76 5.406
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TGF beta-2 messenger RNA (TGFB2 mRNA) DTT TGFB2 1.51E-17 -0.53 -0.77
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT04801017) A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of Oncotelic.